@Noobie Actually to be precise, there are 2 types of vaccines used to protect against polio disease ie. Attenuated oral polio vaccine (OPV) and Inactivated polio vaccine (IPV). So Sinopharm vaccine is using the same technology/ platform as the Inactivated polio vaccine.
I wonder whether UlarSawa bought any stocks after asking so many questions here as well as in other counter forums as well or is he just asking for fun?
@Jolly Nobody here can answer your question why it is not moving despite all the good news regarding bamboo, vaccines etc....We are equally perplexed here...We can only play the waiting game and hope for the best..
BIBP-CorV is one of two inactivated virus COVID-19 vaccine being developed by Sinopharm's Beijing and Wuhan subsidiaries.
By November, nearly one million people had taken the vaccine through China's emergency use program.[8]
As of December 2020, it is currently in Phase III trials in Argentina, Bahrain, Egypt, Morocco, Pakistan, Peru, and United Arab Emirates with over 60,000 people.[8]
On December 9, the UAE announced the official registration of BBICP-CorV after an interim analysis of the Phase III trials showed BBIBP-CorV to have a 86% efficacy against COVID-19 infection.[9]
BIBP-CorV could become a favorable option to vaccinate large parts of the developing world. While mRNA vaccines like BNT162b2 and MRNA-1273 showed higher efficacy of +90%, those present distribution challenges for some nations as they require deep-freeze facilities and trucks. BIBP-CorV could be transported and stored at normal refrigerated temperatures.[10] While Pfizer and Moderna are among developers relying on novel technology, manufacturers have decades of experience with the method Sinopharm is using.[10]
Looks like what i said previously below is correct. This should be the final tranche of PP. Now PP is COMPLETE.
1. Details of Corporate Proposal Involve issuance of new type/class of securities ? No Types of corporate proposal Private Placement Details of corporate proposal Private Placement of up to 20% of the total number of issued shares of Kanger No. of shares issued under this corporate proposal 7,759,261 Issue price per share ($$) Malaysian Ringgit (MYR) 0.1593 Par Value($$) (if applicable) Malaysian Ringgit (MYR) 0.000 Latest issued share capital after the above corporate proposal in the following Units 2,263,027,807 Issued Share Capital ($$) Malaysian Ringgit (MYR) 224,195,582.200 Listing Date 11 Dec 2020
Announcement Info Company Name KANGER INTERNATIONAL BERHAD Stock Name KANGER Date Announced 10 Dec 2020 Category Additional Listing Announcement /Subdivision of Shares Reference Number ALA-10122020-00017
@mikho69 @UlarSawa After digging up all the bursa announcements, the answer is as follows : Total number of shares to be issued for PP is 386,970,684 (Please refer to the link below). Hence, after deducting the no. of PP shares issued for 1st tranche ie. 183,237,544 and no. of PP shares issued for 2nd tranche ie. 195,973,879, the remaining balance should be only 7,759,261 shares left.
However, if we take into account what @x3shphere mentioned above regarding the conversion of redeemable convertible notes (RCN) ie 3,703,703 shares, then total remaining would be 7,759,261 PP + 3,703,703 RCN = 11,462,964 remaining shares (Disclaimer : I have no idea what RCN is and whether it should be added to the number of remaining private placement shares. Perhaps some expert here can enlighten us on this matter)
Kanger should be making the announcement soon regarding the number of shares issued for the 3rd tranche which would be the final tranche and private placement would be complete.
Fake vaccine. Check with Sinopharm HK this morning. No deal between kanger and sino. And there’s no Sinopharm Hunan changde. Only changsha got company. Buy with your own risk. Bye kanger ...
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
NPRA1985
3,415 posts
Posted by NPRA1985 > 2020-12-10 12:46 | Report Abuse
@Noobie Actually to be precise, there are 2 types of vaccines used to protect against polio disease ie. Attenuated oral polio vaccine (OPV) and Inactivated polio vaccine (IPV). So Sinopharm vaccine is using the same technology/ platform as the Inactivated polio vaccine.